Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Cellectar Biosc (NQ: CLRB )

1.940 USD UNCHANGED
Official Closing Price Updated: 7:59 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Cellectar Biosc

< Previous 1 2 3 4 5 6 7 Next >
Cellectar Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia
From GlobeNewswire News Releases
InvestorNewsBreaks – Cellectar Biosciences Inc. (NASDAQ: CLRB) Secures $45M in Underwritten Public Offering and Concurrent Private Placement
From InvestorBrandNetwork
Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement
From GlobeNewswire News Releases
Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement
From GlobeNewswire News Releases
Cellectar Biosciences Announces Proposed Underwritten Public Offering and Concurrent Private Placement
From GlobeNewswire News Releases
Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
From GlobeNewswire News Releases
Cellectar Biosciences’ CLR 131 Demonstrates Preliminary Activity in Phase I Study for Pediatric Brain and Solid Tumors
CLR 131 crosses blood brain barrier delivering drug directly to brain tumors 
From GlobeNewswire News Releases
Cellectar Biosciences to Present at Two Upcoming Investor Conferences
From GlobeNewswire News Releases
Cellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma Patients
40% overall response rate (ORR) with a total administered dose of 60 mCi or greater 
From GlobeNewswire News Releases
Cellectar Presents Poster at the AACR VIRTUAL MEETING: ADVANCES IN MALIGNANT LYMPHOMA
From GlobeNewswire News Releases
Cellectar Reports Second Quarter 2020 Financial Results and Provides a Corporate Update
From GlobeNewswire News Releases
Cellectar Announces Poster Presentation at the International Symposium on Pediatric Neuro-Oncology (ISPNO) Annual Meeting
Data highlight results from the Phase 1 study of CLR 131 in children and adolescents with relapsed/refractory malignancies 
From GlobeNewswire News Releases
Cellectar Announces Poster Presentation of Clinical Data at the American Association of Cancer Research (AACR) Annual Meeting
Data highlight initial results of 100% overall response rate from ongoing Phase 2 trial in Relapsed or Refractory lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s Macroglobulinemia (WM) 
From GlobeNewswire News Releases
Cellectar Appoints Dr. John Friend as Chief Medical Officer
From GlobeNewswire News Releases
Cellectar to be Granted EU Patent for Phospholipid Ether (PLE) Analogs as Cancer-Targeting Drug Vehicles
Covers composition of matter and method of use into 2036 for proprietary PLE analogs in combination with various small molecule chemotherapeutics 
From GlobeNewswire News Releases
NetworkNewsBreaks – Cellectar Biosciences, Inc. (NASDAQ: CLRB) Secures $20.0M in Underwritten Public Offering
From InvestorBrandNetwork
Cellectar Biosciences Announces Closing of $20 Million Underwritten Public Offering
From GlobeNewswire News Releases
Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering
From GlobeNewswire News Releases
Cellectar Granted SME Status by the European Medicines Agency
Designation Comes with Financial and Scientific Incentives 
From GlobeNewswire News Releases
Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia
From GlobeNewswire News Releases
Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131
Patent covers the phospholipid ether (PLE) delivery vehicle combined with I-131 and I-125 
From GlobeNewswire News Releases
Cellectar Reports First Quarter 2020 Financial Results and Provides a Corporate Update
From GlobeNewswire News Releases
Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update
From GlobeNewswire News Releases
Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Mu
From GlobeNewswire News Releases
Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020
From GlobeNewswire News Releases
Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer
From GlobeNewswire News Releases
Cellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL)
From GlobeNewswire News Releases
Cellectar Biosciences to Present at Biotech Showcase 2020
From GlobeNewswire News Releases
Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study
From GlobeNewswire News Releases
Cellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium
Efficacy established in 4th class of molecules utilizing Phospholipid Ether Vehicle 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.